WallStreetZenWallStreetZen

NASDAQ: VRTX
Vertex Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

VRTX past earnings growth

How has VRTX's earnings growth performed historically?
Company
8.33%
Industry
52.08%
Market
61.16%
VRTX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
VRTX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
VRTX's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

VRTX past revenue growth

How has VRTX's revenue growth performed historically?
Company
10.51%
Industry
148.4%
Market
16.96%
VRTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VRTX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
VRTX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

VRTX earnings and revenue history

Current Revenue
$9.9B
Current Earnings
$3.6B
Current Profit Margin
36.7%

VRTX Return on Equity

Current Company
22.6%
Current Industry
-63.5%
Current Market
188%
VRTX's Return on Equity (22.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when VRTX announces earnings.

VRTX Return on Assets

Current Company
17.3%
Current Industry
2.9%
VRTX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

VRTX Return on Capital Employed

Current Company
23.06%
Current Industry
19.5%
VRTX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

VRTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
VRTX$9.87B$4.61B$3.62B+26.49%+11.26%
REGN$13.12B$4.69B$3.95B+20.58%+10.34%
MRNA$6.85B-$3.32B-$4.71B+119.28%N/A
ARGX$38.62M-$209.00M-$320.71M+9.84%N/A
BNTX$4.15B$1.51B$1.01B+96.02%+386.87%
View Top Biotech Stocks

VRTX earnings dates

Next earnings date
May 6, 2024

Vertex Pharmaceuticals Earnings & Revenue FAQ

What were VRTX's earnings last quarter?

On Invalid Date, Vertex Pharmaceuticals (NASDAQ: VRTX) reported Q4 2023 earnings per share (EPS) of $3.76, up 17.87% year over year. Total Vertex Pharmaceuticals earnings for the quarter were $968.80 million. In the same quarter last year, Vertex Pharmaceuticals's earnings per share (EPS) was $3.19.

If you're new to stock investing, here's how to buy Vertex Pharmaceuticals stock.

What was VRTX's earnings growth in the past year?

As of Q2 2024, Vertex Pharmaceuticals's earnings has grown 8.33% year over year. This is 43.75 percentage points lower than the US Biotechnology industry earnings growth rate of 52.08%. Vertex Pharmaceuticals's earnings in the past year totalled $3.62 billion.

What is VRTX's earnings date?

Vertex Pharmaceuticals's earnings date is Invalid Date. Add VRTX to your watchlist to be reminded of VRTX's next earnings announcement.

What was VRTX's revenue last quarter?

On Invalid Date, Vertex Pharmaceuticals (NASDAQ: VRTX) reported Q4 2023 revenue of $2.52 billion up 9.34% year over year. In the same quarter last year, Vertex Pharmaceuticals's revenue was $2.30 billion.

What was VRTX's revenue growth in the past year?

As of Q2 2024, Vertex Pharmaceuticals's revenue has grown 10.51% year over year. This is 137.89 percentage points lower than the US Biotechnology industry revenue growth rate of 148.4%. Vertex Pharmaceuticals's revenue in the past year totalled $9.87 billion.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.